GLP-1 &
Metabolic Response
12 genes, 14 variants, 3 layers -- will it work, why you eat the way you do, and which drug and other medicines to watch. Results are explained in plain language first, with the full technical data and a physician summary in the same report. Includes leptin signaling (LEP/LEPR) and a co-medication watch (CYP2D6, CYP3A4).
⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.
See a fully rendered shareable example -- plain-language results, evidence grades and the physician summary. rsIDs and exact genotypes are hidden in the shareable copy; your report shows them.
RSIDs analyzed in this panel
Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.
Supporting literature
Su QJ et al. Nature 2026 (N=27,885) -- GLP1R rs10305420 (Pro7Leu) and tirzepatide-specific GIPR rs1800437. Dawed AY et al. Lancet Diabetes & Endocrinology 2023 (n=4,571) -- GLP1R rs6923761 and ARRB1 Thr370Met glycemic response. Phan A et al. Obesity 2025 -- semaglutide response by GLP1R genotype and sex. Frayling et al. Science 2007 and Melhorn et al. Am J Clin Nutr 2018 -- FTO. Loos et al. Nat Genet 2008 -- MC4R common variant. t'Hart et al. Diabetes 2013 and Kyriakidou et al. J Pers Med 2022 -- CTRB1 null result for GLP-1 RAs. Jayathilaka et al. Clin Pharmacol Drug Dev 2025 -- CYP2D6 indirect interaction.
Layer 1: Will It Work?
GLP1R encodes the receptor every GLP-1 drug binds. In the largest study to date (Nature 2026, N=27,885), each copy of rs10305420 came with about 0.76 kg of extra weight loss and more nausea while the dose is raised. A second GLP1R variant, rs6923761, slightly reduced the blood-sugar response in a 4,571-patient study, while a small semaglutide study saw faster weight loss in AA carriers -- so we report it as mixed evidence. ARRB1 Thr370Met, which helps reset the receptor, was linked to a bigger HbA1c drop. TCF7L2 rounds out the layer for blood-sugar context.
Layer 2: Why You Eat the Way You Do
FTO rs9939609 carriers respond more strongly to food cues -- fMRI studies show it -- and GLP-1 drugs act on these same appetite circuits. MC4R rs17782313 is a common variant near a key fullness gene (not the rare inherited MC4R changes, which need sequencing). CNR1 and LEP/LEPR add craving and leptin-signaling context. None of these predict how well a drug will work; they explain the appetite biology the drug is acting on.
Layer 3: Which Drug, What to Watch
GIPR rs1800437 matters only for tirzepatide: carriers had more nausea and vomiting on tirzepatide but not on semaglutide, and people with two copies of both this and the GLP1R variant had 14.8-fold odds of vomiting on tirzepatide (Nature 2026). CTRB1 is included with full disclosure that it did not predict GLP-1 response (OR 1.12, p=0.84). CYP2D6 and CYP3A4 flag other medicines whose absorption may shift when a GLP-1 drug slows stomach emptying.
How to read this report
Results come in plain language first. Dots show how many copies of a studied variant you carry (0, 1 or 2) and never mean good or bad -- the text says whether a finding is a watch-out, favorable, or still being studied. Every variant carries a Level A or Level B evidence badge, and a physician summary page restates the findings for a clinical visit. This report does not recommend for or against any medication.
This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com
- ✓Layer 1 -- Will It Work? GLP1R (3 variants), ARRB1 Thr370Met, TCF7L2 -- genes in the drug's direct pathway
- ✓Layer 2 -- Why You Eat: FTO, MC4R, CNR1, LEP/LEPR -- appetite, cravings and fullness signaling
- ✓Layer 3 -- Which Drug & What to Watch: GIPR (tirzepatide-specific), CTRB1 (null-result disclosure), CYP2D6 + CYP3A4 (co-medication watch)
- ✓Plain-language first: 0/1/2-copy dot meters that never imply good or bad, then a full technical table and a clinician summary page
- ✓Level A / Level B evidence grading on every variant, including genes that did not predict response
- ✓Powered by Su et al. Nature 2026 GWAS (N=27,885) and Dawed et al. Lancet Diabetes & Endocrinology 2023 (n=4,571)
⚠ Research Use Only · Not FDA cleared